Indian Companies Dominate Competitive Generic Approvals by FDA 

FDA approved drugs that have none or few generic versions are designated as Competitive Generics with special incentives to developers under a law passed in 2017 aimed to avoid monopolies that lead to price gouging. Manufacturers based in India dominate the development of competitive generis with almost 55% of all such generics developed by Indian … Read more

The RMAT Designation Seems To Be Tougher Than the BTD

When the Regenerative Medicine Advance Therapy (RMAT) designation was proposed in 2016, it was assumed to be an easier expedited approval pathway specific for stem cells and other regenerative therapies, compared to the Breakthrough Therapy (BTD) designation. But it with about 40% approval rates and only 3 approvals, it may be turning out to be … Read more

FDA Defines Parties Involved in Manufacture and Distribution of Drugs

Manufacture and distribution of drugs and biologics involve various parties with diverse responsibilities, and it was always confusing as to what regulatory requirements apply to them, till now. Who needs to register with FDA, who needs to pay fees, who needs to be licensed by other authorities, etc.? This week, FDA’s newest Guidance Document list … Read more

Scientific Data Versus Anecdotes: What Role Should They Play in FDA Decisions

In an ideal world, regulatory policies and laws are based on unquestionable data from high quality scientific research but should there be other criteria or a standard for weighing unconventional data when the scientific data is not sufficient? There are numerous instances where claims of benefits by patient were not supported by the clinical trial … Read more

Breakthrough Therapy Designation is Not Permanent: FDA Guidance Emphasizes

In one of its shortest guidance documents, FDA clarified that the highly coveted and tough to get Breakthrough Therapy Designation (BTD) can be rescinded for multiple reasons. The description of the conditions for rescinding BTDs are not new and have been defined in previous FDA documents, so the purpose of this new guidance is not … Read more

Dietary Supplements for Cardiovascular Disease and Cancer?

An analysis conducted by the US Preventive Services Task Force (USPSTF) found that dietary supplements are not effective in preventing or reducing the incidence of cardiovascular disease and cancer, and that supplements rich in beta carotene are indeed more harmful than beneficial. These conclusions, based on the pooled analysis of published clinical trial results, raise … Read more

FDA Releases an Updated List of Approved Drugs with No Generics

Since the infamous case of Daraprim price gouging in 2015 where a drug company bought the rights to a drug with no generics and raised the price by 5000% overnight due to its monopoly, FDA has been publishing a list of approved drugs with no patent protection and no generic versions to encourage the industry … Read more

Is FDA In a Bind With the Canadian Approval for the ALS drug?

This week Amylyx’s ALS drug was approved by the Canadian regulators raising speculations that this would make it very hard for FDA to reject this drug despite the negative vote by the FDA’s Advisory Committee which based its recommendation on the underwhelming clinical trial data from the one pivotal trial conducted by the company. But … Read more

FDA Will Allow EUA Data To be Reused for Full Approval

In the last two and half years, FDA has approved hundreds of EUAs for various products for the diagnosis, management, and treatment of Covid-19. However, EUAs are temporary permits to sell products which ends when the emergency is declared to be over, i.e., the emergency declaration is withdrawn. An appropriate market approval (510k, PMA, NDA … Read more